Podcasts about screening test

Die Krebsmedizin steht vor einem Wendepunkt: Die Liquid Biopsy könnte Tumore früher erkennen als bisherige Methoden. Besonders bei aggressiven Krebsarten wie Bauchspeicheldrüsenkrebs könnte dies entscheidend sein. Bauchspeicheldrüsenkrebs gehört zu den tückischsten Krebsarten. Der Tumor wächst oft unbemerkt, zeigt kaum Symptome und wird meist spät entdeckt. Dann ist Heilung oft nicht mehr möglich, was die Überlebensrate senkt. Ein weiteres Problem ist die Biologie des Tumors. Er bildet früh Metastasen und schafft ein Umfeld, das das Immunsystem hemmt und Therapien erschwert. Hier greift die Liquid Biopsy. Statt Gewebeproben analysiert man Blutproben, um Tumorspuren wie zirkulierende Tumor-DNA oder Krebszellen zu finden. Der große Vorteil: - Nicht-invasiv (keine Operation nötig) - Wiederholbar (Verlaufskontrolle möglich) - Ganzheitlicher Blick auf den Tumor Diese Methode könnte nicht nur bei der Diagnose helfen, sondern auch Therapien individueller gestalten und deren Erfolg überwachen. Trotz der vielversprechenden Technologie gibt es Hürden. Für den Einsatz als Screening-Test bei Gesunden muss sie extrem zuverlässig sein. Ein zentrales Problem: - Falsch-positive Ergebnisse könnten unnötige Angst und belastende Untersuchungen auslösen - Kleinste Tumorsignale müssen sicher erkannt werden Gerade bei seltenen Krebsarten wie Bauchspeicheldrüsenkrebs ist das Verhältnis von Nutzen und Aufwand kritisch. Derzeit arbeitet man intensiv an Multi-Cancer-Tests, die mehrere Krebsarten gleichzeitig erkennen sollen. Erste Studien zeigen, dass sogar frühe Tumorstadien detektierbar sind, doch es besteht noch Verbesserungsbedarf bei Genauigkeit und Sensitivität. Ein vielversprechender Ansatz ist die Kombination von Liquid Biopsy mit künstlicher Intelligenz. Durch die Analyse komplexer Datenmuster könnten Tumorsignale präziser identifiziert werden. Die Liquid Biopsy könnte die Krebsdiagnostik revolutionieren. Vor allem bei schwer erkennbaren Tumoren wie Bauchspeicheldrüsenkrebs könnte sie Leben retten. Bis zur breiten Anwendung im Gesundheitssystem wird es jedoch noch Jahre dauern. Entscheidend wird sein, dass die Tests nicht nur technisch funktionieren, sondern auch die Überlebenschancen nachweislich verbessern. Die Vision bleibt klar: Ein einfacher Bluttest als Teil der Vorsorgeuntersuchung – und Krebs wird erkannt, bevor er zur Gefahr wird.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - ဒၢလီၢ်ခိၣ်ထိးခဲစၢၣ်တၢ်ဆါန့ၣ်မ့ၢ်တၢ်လၢတၢ်ဒီသဒၢဆိအီၤန့ၢ်တခါ, နာ်သက့ ထဲဒၣ်လၢနမ့ၢ်ဃုထံၣ်သ့ၣ်ညါချုးန့ၢ်အီၤလၢအဆိအချ့အဂီၢ်န့ၣ်လီၤ. ခီဖျိလၢလုၢ်လၢ်ဆဲးလၤဒီး နီၣ်ကစၢ်တဂၤအဂ့ၢ် တၢ်အိၣ်သး အတၢ်တြီတံာ်သ့ၣ်တဖၣ်အဃိ အါစုအါဘျီန့ၣ် ပိာ်မုၣ်သ့ၣ်တဖၣ် ထုးယံၤအသးလၢ တၢ်မၤကွၢ် ဒၢလီၢ်ခိၣ်ထိးခဲစၢၣ်တၢ်ဆါန့ၣ်လီၤ. နာ်သက့ ခဲကနံၣ်အံၤန့ၣ်, မ့ၢ်လၢဟီၣ်ခိၣ်ဒီဘ့ၣ်တၢ်မၤကွၢ်ကျိၤကျဲလၢအဂ့ၤကတၢၢ် အတၢ်မၤစၢၤအဃိ, မ့ၢ်တုၤလီၤဖဲ ၂ဝ၃၅နံၣ်န့ၣ် အီစထြ့လယါကီၢ်အိၣ်ဒီးတၢ်ပညိၣ်လၢ အကဒုးဟးဂီၤကွံာ် ဒၢလီၢ်ခိၣ်ထိးခဲစၢၣ်တၢ်ဆါတုၤအန့ၢ်န့ၣ်လီၤ. ပိာ်မုၣ်အထူအထံးဟဲန့ၢ်လၢ အအိၣ်ဒီးလုၢ်လၢ်ဆဲးလၤတၢ်တြီတံာ်သ့ၣ်တဖၣ်အဂီၢ်န့ၣ် တၢ်မၤကွၢ်အံၤအိၣ်ဒီးတၢ်ပူၤဖျဲးန့ၣ်လီၤ. လၢတၢ်ခဲလၢာ်အဖီခိၣ် တၢ်အဂ့ၤအကတၢၢ်န့ၣ်မ့ၢ်ဝဲ တၢ်အံၤမ့ၢ်တၢ်လၢအမၤပူၤဖျဲးနသးသမူ မ့တမ့ၢ် ပှၤလၢအအိၣ်ဘူးအိၣ်တံၢ်ဒီးနၤတဂၤဂၤ အသးသမူသ့ဝဲန့ၣ်လီၤ.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - अस्ट्रेलियाले विश्वका नवीनतम परीक्षण विधिहरूको सहयोगमा सन् २०३५ सम्म पाठेघरको क्यान्सर उन्मुलन गर्ने लक्ष्य राखेको छ। अस्ट्रेलिया बुझ्नुहोस्‌को यो अङ्कमा हामी 'सर्भिकल स्क्रीनिङ टेस्ट' भनेको के हो र कहाँ उपलब्ध हुन्छ भन्ने बारेमा चर्चा गर्दै छौँ।

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - Раку шийки матки можна запобігти, але лише якщо виявити його на ранній стадії. Культурні та особисті бар'єри часто призводять до того, що жінки уникають тестування на рак шийки матки. Але тепер, за допомогою провідного світового тесту, Австралія прагне ліквідувати рак шийки матки до 2035 року. Цей тест є безпечним та культурно чутливим варіантом для жінок з будь-яким походженням. Найкраще те, що він може врятувати ваше життя — або життя когось із ваших близьких.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - ມະເຮັງປາກມົດລູກ ສາມາດປ້ອງກັນໄດ້, ຂໍພຽງແຕ່ ທ່ານກວດພົບຢ່າງໄວເທົ່ານັ້ນ. ອຸບປະສັກສ່ວນຕົວ ແລະທາງວັດທະນະທັມ ມັກຫມາຍຄວາມວ່າ ຜູ້ຍິງຊັກຊ້າໃນການກວດເບິ່ງມະເຮັງປາກມົດລູກ. ແຕ່ບັດນີ້ ດ້ວຍຄວາມຊ່ອຍເຫລືອຂອງການກວດ ທີ່ນຳໜ້າຂອງໂລກ, ອອສເຕຣເລັຍ ມີເປົ້າຫມາຍ ທີ່ຈະກໍາຈັດມະເຮັງປາກມົດລູກ ພາຍໃນປີ 2035ການກວດເປັນທາງເລືອກທີ່ປອດພັຍ ແລະໃຫ້ຄວາມສຳຄັນ ທາງວັດທະນະທັມສໍາລັບຜູ້ຍິງ ຈາກທຸກພື້ນຖານ. ສິ່ງດີທີ່ສຸດແມ່ນວ່າ ມັນສາມາດຊ່ວຍຊີວິດຂອງທ່ານໄດ້—ຫລື ຊີວິດຂອງຄົນ ທີ່ໃກ້ຊິດກັບທ່ານ.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - Saratani ya Kizazi inaweza zuiliwa, kama ina gunduliwa mapema. Vizuizi vya kitamaduni na kibinafsi mara nyingi vime kuwa na maana kwamba, wanawake wanachelewesha kufanya uchunguzi wa saratani ya kizazi. Ila sasa, kwa msaada wa kipimo kinacho ongoza duniani, Australia ina lenga kutokomeza saratani ya kizazi kufikia mwaka wa 2035. Uchunguzi huo ni salama, na kitamaduni ni chaguo nyeti kwa wanawake kutoka mazingira yote. Muhimu zaidi, kipimo hicho kinaweza okoa maisha yako au mtu wa karibu yako.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - Cancer tsev me nyuam yog ib co muaj peev tiv thaiv tau, tab sis tsuas yog koj txheeb tau thaum tseem mob ntxov xwb. Tej teeb meem cuam tshuam txog tej kab lis kev cai thiab ntug tug tau ua rau tej poj niam pheej lug tsis mus txheeb seb puas mob cancer tsev me nyuam. Tab sis tam sim no tau muaj ntiaj teb ib co kev sim los pab lawm, thiab Australia muaj hom phiaj yuav los txo kom muaj neeg mob cov cancer tsev me nyuam no tsawg txog xyoo 2035. Cov kev txheeb no yeej siv tau txais kev nyab xeeb thiab siv haum raws li tej kab lis kev cai rau tej poj niam coj ntseeg ntau yam kab lis kev cai. Thiab qhov zoo tshaj plaws ces tej zaum cov kev txheeb no kuj yuav pab cawm tau koj los yog ib tug txheeb ze koj txoj siab thiab.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - Умайн хүзүүний хорт хавдраас урьдчилан сэргийлэх боломжтой. Гэхдээ зөвхөн эрт үед нь илрүүлж чадвал. Гэвч соёлын болон хувийн шалтгаануудын улмаас эмэгтэйчүүд уг шинжилгээнээс зайлсхийдэг. Харин одоо дэлхийд тэргүүлэх тестийн тусламжтайгаар Австрали 2035 он гэхэд умайн хүзүүний хорт хавдрыг бүрэн устгах зорилготой байна. Энэхүү тест нь бүх эмэгтэйчүүдэд аюулгүй бөгөөд соёлын онцлогийг харгалзсан сонголттой байдаг. Хамгийн гол нь энэ тест таны эсвэл ойр дотны хүмүүсийн тань амь насыг аварч чадах чухал шинжилгээ юм.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - មហារីកមាត់ស្បូនគឺអាចបង្ការបាន ប៉ុន្តែលុះត្រាតែអ្នកបានដឹងទាន់ពេលវេលា។ រនាំងវប្បធម៌ និងឧបសគ្គផ្ទាល់ខ្លួន មានន័យថា ជាញឹកញាប់ស្ត្រីពន្យារពេលការពិនិត្យមហារីកមាត់ស្បូន។ ប៉ុន្តែឥឡូវនេះ ដោយមានជំនួយពីការធ្វើតេស្តឈានមុខគេលើពិភពលោក អូស្ត្រាលីមានបំណងលុបបំបាត់ជំងឺមហារីកមាត់ស្បូននៅត្រឹមឆ្នាំ 2035។ នៅថ្ងៃនេះ អ្នកនឹងបានស្តាប់ឮពីរបៀបដែលការធ្វើតេស្តនេះគឺជាជម្រើសសុវត្ថិភាព និងយល់ពីចំណុចរសើបខាងវប្បធម៌សម្រាប់ស្ត្រីមកពីគ្រប់មជ្ឈដ្ឋាន។ អ្វីដែលប្រសើរបំផុតនោះ គឺវាអាចសង្គ្រោះជីវិតអ្នកបាន។

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - ගැබ්ගෙල පිළිකා හෙවත් Cervical cancer වළක්වා ගත හැකි නමුත් ඒවා වලක්වාගත හැක්කේ එය කලින් හඳුනාගත හොත් පමණයි. මේ හේතුවෙන් ඕස්ට්‍රේලියාවේ වෙසෙන සියලුම පසුබිම්වල සිටින කාන්තාවන් සඳහා මෙම ගැබ්ගෙල පිළිකා පරීක්ෂාව අත්‍යවශ්‍ය වන්නේ අයි සහ එය කෙතරම් ආරක්ෂිතද යන්න පිළිබඳව තොරතුරු මේ විශේෂාන්ගයෙන් ගෙන එනවා.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - 子宮頸がんは、早期に発見すれば予防できる病気です。しかし文化的、または個人的な理由から、検診を避ける女性が少なくありません。オーストラリアは現在、最新の検査を導入し、2035年までに子宮頸がんの根絶を目指しています。この検査は、安全で、文化的な背景にも配慮された方法であり、あらゆる女性が受けやすいものです。何よりも、あなた自身、あるいはあなたの大切な人の命を救う可能性があります。

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - Penceşêr yan seretana malzarokî - cervical cancer dikare were pêşîlêgirtin, heke hûn zû li xwe bipirsin. Astengiyên çandî û kesane gelek caran bûne sedema ku jin têsta penceşêra malzarokî dereng bixin. Lê niha bi alîkariya ceribandineke pêşeng a cîhanê, Australya armanc dike ku heta sala 2035an seretana malzarokî ji holê rake.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - 子宮頸癌是可以預防的，但前提是能夠及早發現。但文化及個人因素往往導致女性避免接受子宮頸癌檢測。如今，憑藉一項世界領先的檢測技術，澳洲目標希望在2035年前消除子宮頸癌。此檢測對所有背景的女性而言既安全又具文化敏感性。最重要的是，它可能挽救你或身邊某人的生命。

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - സ്ത്രീകളിൽ ഏറ്റവും കൂടുതലായി കണ്ടുവരുന്ന അർബുദങ്ങളിലൊന്നാണ് സെർവിക്കൽ കാൻസർ. ഇതിൻറെ ലക്ഷണങ്ങൾ നേരത്തെ കണ്ടെത്തേണ്ടത് വളരെ പ്രധാനമാണ്. സെർവിക്കൽ കാൻസർ സ്‌ക്രീനിങ്ങിനെ കുറിച്ച് വിശദമായി കേൾക്കാം, ഓസ്ട്രേലിയൻ വഴികാട്ടിയിലൂടെ...

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - سرطان دهانه رحم قابل پیشگیری است، اما تنها در صورتی که آن را زود تشخیص دهید.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - 宫颈癌是可以预防的，但前提是及早发现。 文化和个人障碍常常导致女性推迟宫颈癌筛查。 但现在，借助一项世界领先的检测技术，澳大利亚的目标是到2035年消除宫颈癌。 今天，您将了解到这项检测对于所有背景的女性来说都是一个安全且具有文化敏感性的选择。 最重要的是，它可以挽救您的生命。 （点击音频收听详细报道）

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - Những rào cản văn hoá và tâm lý từ lâu đã khiến nhiều phụ nữ trì hoãn việc tầm soát ung thư cổ tử cung. Nhưng nay, với sự ra đời của một xét nghiệm hàng đầu thế giới, Úc đang đặt mục tiêu loại trừ ung thư cổ tử cung vào năm 2035.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - มะเร็งปากมดลูกสามารถป้องกันได้ หากตรวจพบตั้งแต่ระยะแรก และออสเตรเลียตั้งเป้าที่จะขจัดมะเร็งปากมดลูกภายในปี 2035 ด้วยวิธีการตรวจคัดกรองมะเร็งปากมดลูกที่ปลอดภัยและเพิ่มความสบายใจ

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - سرطان دهانه رحم قابل جلوگيرى است، اما تنها اگر زود تشخیص داده شود. موانع فرهنگی و شخصی اكثراً باعث مى شود كه زنان در انجام آزمایش دهانه رحم تأخیر کنند. اما آسترالیا اكنون با کمک یک آزمایش جهانى پیشرفته تصمیم دارد تا سال ۲۰۳۵ سرطان دهانه رحم را ریشه‌کن کند. در این قسمت "روزنه‌ای به آسترالیا" در اين مورد صحبت مى كنيم که این آزمایش چگونه یک گزینه مصوون و حساس به فرهنگ‌های مختلف برای زنان دارى هرگونه پيشينه‌اى است. بهترین مزيت آن این است که ممکن جان شما را نجات دهد.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - সার্ভিকাল ক্যানসার প্রতিরোধযোগ্য, কিন্তু কেবল তখনই যদি এটি শুরুতেই নির্ণয় করা যায়। সাংস্কৃতিক ও ব্যক্তিগত প্রতিবন্ধকতার কারণে অনেক সময় নারীরা সার্ভিকাল ক্যানসার স্ক্রিনিং করতে দেরি করে ফেলেন। কিন্তু এখন বিশ্বের অন্যতম সেরা একটি টেস্টের সাহায্যে অস্ট্রেলিয়া ২০৩৫ সালের মধ্যে সার্ভিকাল ক্যানসার নির্মূল করার লক্ষ্য নিয়েছে।

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - 자궁경부암은 조기에 발견할 경우 예방이 가능합니다. 그러나 문화적·개인적 장벽으로 인해 여성들이 자궁경부암 검사를 기피하는 경우가 많았습니다. 이제 세계 최고 수준의 검사의 도움으로 호주는 2035년까지 자궁경부암을 근절하는 것을 목표로 하고 있습니다. 이 검사는 모든 배경의 여성들에게 안전하고 문화적 감수성을 고려한 선택지입니다. 무엇보다도 이 검사는 여러분의 생명을 구할 수 있으며, 가까운 사람의 생명을 구할 수도 있습니다.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - يُعد سرطان عنق الرحم من الأمراض التي يمكن الوقاية منها، بشرط عند الكشف المبكر.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - Kanker serviks dapat dicegah, tetapi hanya jika terdeteksi dini. Hambatan budaya dan pribadi seringkali membuat perempuan menghindari tes kanker serviks. Namun kini, dengan bantuan tes terkemuka dunia, Australia menargetkan penghapusan kanker serviks pada tahun 2035.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - கர்ப்பப்பை வாய்ப் புற்றுநோயை ஆரம்பத்திலேயே கண்டறிந்தால் அதனைத் தடுக்க முடியும். ஆனால், கலாச்சார மற்றும் தனிப்பட்ட தடைகள் காரணமாக பெரும்பாலான பெண்கள் கர்ப்பப்பை வாய்ப் புற்றுநோய் பரிசோதனையைத் தவிர்க்கின்றனர் என்று தரவுகள் சொல்கின்றன. ஒருவரின் உயிரைக் காப்பாற்றும் கர்ப்பப்பை வாய்ப் பரிசோதனை குறித்து Melissa Compagnoni ஆங்கிலத்தில் தயாரித்த விவரணத்தைத் தமிழில் எடுத்து வருகிறார் றேனுகா துரைசிங்கம்.

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - ካንሰር ማህጸን ክትከላኸሎ ዝከኣል ብኣጋኡ እንተ ተመርሚርካ ጥራይ እዩ ። ብባህላውን ውልቃውን ማሕለኻታት መብዛሕትኡ ግዜ ደቀንስትዮ መንሽሮ ማህጸን ካብ ምምርማር ከም ዝርሕቃ እዩ ዝሕብር ። ሕጂ ግን ብዓለምለኸ ደረጃኡ ቅቡል ዝኾነ ብዝግበር ምርመራ: ኣውስትራልያ ኣብ 2035 መንሽሮ ማህጸን ንምጥፋእ ዒላማ ግይራ ትሰርሕ ኣላ ። እቲ መርመራ ካብ ኩሉ ድሕረ ባይታ ንዝመጻ ደቂ ኣንስትዮ ውሑስን ባህላውን ዝኾነ ኣማራጺ እዩ ። ልዕሊ ኵሉ ድማ ህይወትኪ ወይ ህይወት ናይታ እትቐርብያ ሰብ ከድሕን ይኽእል እዩ ።

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you. - سروائیکل کینسر سے بچاؤ ممکن ہے لیکن صرف اس صورت میں جب آپ اسے جلد پکڑ لیں۔ ثقافتی اور ذاتی رکاوٹوں کا اکثر مطلب یہ ہوتا ہے کہ خواتین سروائیکل کینسر کی جانچ سے گریز کرتی ہیں۔ لیکن اب عالمی سطح پر معروف ٹیسٹ کی مدد سے، آسٹریلیا 2035 تک سروائیکل کینسر کو ختم کرنے کا ہدف رکھتا ہے۔ یہ ٹیسٹ تمام پس منظر کی خواتین کے لیے ایک محفوظ اور ثقافتی طور پر ایک اچھا انتخاب ہے۔ سب سے بہتر یہ آپ کی یا آپ کے کسی قریبی کی جان بچا سکتا ہے۔

Cervical cancer is preventable, but only if you catch it early. Cultural and personal barriers have often meant that women avoid cervical cancer testing. But now with the help of a world-leading test, Australia is aiming to eliminate cervical cancer by 2035. The test is a safe and culturally sensitive option for women from all backgrounds. Best of all it could save your life—or that of someone close to you.

Can you prevent cervical cancer? How do you prevent cervical cancer? Can I check for cervical cancer at home? Who should get screened for cervical cancer? Does the HPV vaccine work? Our guest is Ritu Nayar, MD, professor of pathology and medical education and executive vice chair of pathology at Northwestern University Feinberg School of Medicine. In this episode, Dr. Nayar talks about where cervical cancer rates are on the rise and how new screening tools can help reverse that trend. American Medical Association CXO Todd Unger hosts.

Broadcast from KSQD, Santa Cruz on 7-10-2025: Dr. Dawn responds to an email about lion's mane mushroom blood thinning properties. Lion's mane contains hericenones that inhibit platelet aggregation but promote nerve cell growth. People on blood thinners like Eliquis or those with bleeding disorders should stop these supplements before surgery. She recommends lion's mane for cognitive preservation effects despite bleeding risks, emphasizing the need to balance benefits versus risks. An emailer asks about Fatty15 (C15:0 pentadecanoic acid) supplements marketed for longevity. Dr. Dawn finds promising research, however, most studies are in animals with limited human data. She warns against over-supplementation and recommends food-first approaches, suggesting cheaper alternatives like berberine may provide similar benefits. A visiting guest asks about continuing L-arginine after blood pressure normalized. Dr. Dawn recommends continuing L-arginine as it helps produce nitric oxide and prevents age-related arterial stiffening. She explains how blood vessel elasticity decreases with age, creating feed-forward cycles leading to permanent hypertension. The guest also asks about iodine safety - Dr. Dawn confirms 1mg daily is safe, noting Japanese populations consume up to 4mg daily without problems. Another visiting guest inquires about memory-boosting supplements (nootropics). Dr. Dawn identifies nicotine and caffeine as effective options, mentioning she uses nicotine patches for test-taking focus. She discusses lion's mane as effective for cognitive enhancement and coffee blends combining both ingredients. A caller asks about tirzepatide (Mounjaro) for weight loss at age 73, concerned about muscle loss. Dr. Dawn emphasizes the importance of branched-chain amino acids and 20-30 grams of protein before exercise for older adults to build muscle protein. She explains younger people can build muscle while fasting, but older adults need circulating protein during exercise to activate muscle-building DNA. She recommends alternating upper and lower body workouts and checking testosterone levels. Another caller asks about rapid resting pulse rate (80-100 bpm) at age 74. Dr. Dawn suggests checking blood pressure, as low blood pressure can cause compensatory heart rate increases. She explains age-related changes in blood vessel reflexes that can cause blood pooling in legs and orthostatic changes. The caller also complains about pharmaceutical advertising, prompting Dr. Dawn to criticize direct-to-consumer drug marketing for creating artificial needs through emotional manipulation. Dr. Dawn warns against P-Tau217 blood testing for Alzheimer's screening, calling it inadequate for general population screening. The test has poor predictive value below level 10, creating many false positives in low-risk populations. She criticizes associated drugs like donanemab (Kisunla) for severe side effects including brain swelling and hemorrhage. Instead, she recommends lifestyle interventions: exercise, stress control, adequate sleep, reduced alcohol and sugar intake for memory concerns. She criticizes FDA approval of a new blood test for colon cancer screening with 83% sensitivity for detecting existing cancers but poor sensitivity for precancerous polyps. Dr. Dawn criticizes this as inadequate screening since it detects cancer after "the horse has left the barn" rather than preventing it. In closing remarks with her impromptu guests, Dr. Dawn addresses a question about intermittent fasting and exercise timing. She explains that exercising while fasting provides cardiovascular benefits but won't build muscle mass in older adults. She recommends bioimpedance analysis testing to track lean body mass annually in seniors and emphasizes the importance of progressive resistance training to prevent age-related muscle loss.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Naveen Jain. He is an indomitable force fueled by unyielding curiosity and an unwavering commitment to propel humanity toward a future of limitless possibilities. As the Founder and CEO of Viome, Naveen spearheads a revolution in personalized health and human longevity that extends far beyond conventional approaches. Viome's groundbreaking mRNA analysis with an AI-driven platform analyzes the intricate interplay between food, our microbiome, and our human cells and pioneers early diagnostics and preventative wellness strategies. By decoding the molecular information within each individual, Viome aims to empower people to take proactive steps towards health and longevity, preventing chronic diseases before they manifest. Naveen's visionary leadership has garnered numerous accolades, reflecting his unwavering dedication and trailblazing spirit. From being recognized as "Entrepreneur of the Year" by Ernst & Young to receiving the esteemed "Most Creative Person" title from Fast Company, his exceptional contributions have left an indelible mark. Naveen's brilliance and philanthropic endeavors have earned him prestigious honors, including the esteemed "Lifetime Achievement Award" by Red Herring and the notable "Medal of Honor" by Ellis Island. Notably, Town & Country Magazine celebrated him as one of the "Top 50 Philanthropists," further underscoring his commitment to making a meaningful impact. Company Description *We provide the industry’s only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need. By joining Viome, you are joining a revolutionary movement. A movement that – for the first time in human history – will make becoming ill a matter of choice, and not simply bad luck. Scientists have worked for over a decade to develop this technology that offers unprecedented visibility into your body. With this, we can create a unique profile of the biochemistry and ecosystem inside of you, and make personalized, actionable, and adaptive recommendations for your health. Our at-home tests are not just one-time tests, but your true health companion, enabling you to monitor your health over time. Your results and recommendations adapt to your changing ecosystem so you are always aware and taking action towards maximizing your vitality and lifespan. The Viome team is made up of scientists, engineers, researchers and entrepreneurs who are passionate about radically improving the wellness of our customers. #BEST #STRAW #SHMSSupport the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Naveen Jain. He is an indomitable force fueled by unyielding curiosity and an unwavering commitment to propel humanity toward a future of limitless possibilities. As the Founder and CEO of Viome, Naveen spearheads a revolution in personalized health and human longevity that extends far beyond conventional approaches. Viome's groundbreaking mRNA analysis with an AI-driven platform analyzes the intricate interplay between food, our microbiome, and our human cells and pioneers early diagnostics and preventative wellness strategies. By decoding the molecular information within each individual, Viome aims to empower people to take proactive steps towards health and longevity, preventing chronic diseases before they manifest. Naveen's visionary leadership has garnered numerous accolades, reflecting his unwavering dedication and trailblazing spirit. From being recognized as "Entrepreneur of the Year" by Ernst & Young to receiving the esteemed "Most Creative Person" title from Fast Company, his exceptional contributions have left an indelible mark. Naveen's brilliance and philanthropic endeavors have earned him prestigious honors, including the esteemed "Lifetime Achievement Award" by Red Herring and the notable "Medal of Honor" by Ellis Island. Notably, Town & Country Magazine celebrated him as one of the "Top 50 Philanthropists," further underscoring his commitment to making a meaningful impact. Company Description *We provide the industry’s only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need. By joining Viome, you are joining a revolutionary movement. A movement that – for the first time in human history – will make becoming ill a matter of choice, and not simply bad luck. Scientists have worked for over a decade to develop this technology that offers unprecedented visibility into your body. With this, we can create a unique profile of the biochemistry and ecosystem inside of you, and make personalized, actionable, and adaptive recommendations for your health. Our at-home tests are not just one-time tests, but your true health companion, enabling you to monitor your health over time. Your results and recommendations adapt to your changing ecosystem so you are always aware and taking action towards maximizing your vitality and lifespan. The Viome team is made up of scientists, engineers, researchers and entrepreneurs who are passionate about radically improving the wellness of our customers. #BEST #STRAW #SHMSSee omnystudio.com/listener for privacy information.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Naveen Jain. He is an indomitable force fueled by unyielding curiosity and an unwavering commitment to propel humanity toward a future of limitless possibilities. As the Founder and CEO of Viome, Naveen spearheads a revolution in personalized health and human longevity that extends far beyond conventional approaches. Viome's groundbreaking mRNA analysis with an AI-driven platform analyzes the intricate interplay between food, our microbiome, and our human cells and pioneers early diagnostics and preventative wellness strategies. By decoding the molecular information within each individual, Viome aims to empower people to take proactive steps towards health and longevity, preventing chronic diseases before they manifest. Naveen's visionary leadership has garnered numerous accolades, reflecting his unwavering dedication and trailblazing spirit. From being recognized as "Entrepreneur of the Year" by Ernst & Young to receiving the esteemed "Most Creative Person" title from Fast Company, his exceptional contributions have left an indelible mark. Naveen's brilliance and philanthropic endeavors have earned him prestigious honors, including the esteemed "Lifetime Achievement Award" by Red Herring and the notable "Medal of Honor" by Ellis Island. Notably, Town & Country Magazine celebrated him as one of the "Top 50 Philanthropists," further underscoring his commitment to making a meaningful impact. Company Description *We provide the industry’s only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need. By joining Viome, you are joining a revolutionary movement. A movement that – for the first time in human history – will make becoming ill a matter of choice, and not simply bad luck. Scientists have worked for over a decade to develop this technology that offers unprecedented visibility into your body. With this, we can create a unique profile of the biochemistry and ecosystem inside of you, and make personalized, actionable, and adaptive recommendations for your health. Our at-home tests are not just one-time tests, but your true health companion, enabling you to monitor your health over time. Your results and recommendations adapt to your changing ecosystem so you are always aware and taking action towards maximizing your vitality and lifespan. The Viome team is made up of scientists, engineers, researchers and entrepreneurs who are passionate about radically improving the wellness of our customers. #BEST #STRAW #SHMSSteve Harvey Morning Show Online: http://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Visit NascentMC.com for medical writing assistance. Visit learnAMAstyle.com for information on AI in Medical Writing and Editing - **mRNA Anti-EBV Cancer Vaccine**: The novel mRNA therapeutic cancer vaccine WGc-043 has been approved for clinical trials by the FDA, targeting Epstein-Barr virus (EBV) related cancers such as nasopharyngeal carcinoma and natural killer T-cell lymphoma. It stimulates the immune system to respond against EBV and associated malignancies, showing superior efficacy and safety in preliminary trials. A phase 1 clinical trial is currently focusing on patients who have failed second-line therapies, aiming to determine the optimal dose and evaluate safety and efficacy metrics. - **BTX-9341 for Breast Cancer**: The FDA has approved the investigational new drug application for BTX-9341, a novel cyclin-dependent kinase (CDK) 4/6 bifunctional degrader, intended for hormone receptor-positive, HER2-negative breast cancer resistant to existing CDK4/6 inhibitors. This drug targets and degrades CDK4/6 proteins, crucial for cancer cell cycle regulation, aiming to overcome resistance to current treatments. A phase 1 trial will assess its safety, biological activity, and efficacy both as monotherapy and combined with fulvestrant. - **Nivolumab Hyaluronidase Formulation**: The FDA has accepted a Biologics License Application for a subcutaneous formulation of nivolumab co-formulated with recombinant human hyaluronidase, enhancing convenience by reducing administration time compared to the intravenous version. This application includes all previously approved solid tumor indications for nivolumab, with a PDUFA date set for February 28, 2025. The subcutaneous version aims to provide faster and easier administration, supported by data from the Phase 3 CheckMate-67T study. - **ColoSense Colorectal Cancer Screening Test**: The FDA has approved ColoSense, a noninvasive colorectal cancer screening test using multi-target stool RNA for adults aged 45 and older at average risk. ColoSense, distinct from traditional FOBT tests, uses RNA biomarkers to detect CRC with high sensitivity and has shown promising results in clinical trials, detecting 93% of CRC cases and 45% of advanced adenomas in average-risk individuals. This new test offers a significant improvement in sensitivity and specificity over existing methods. For the complete shownotes visit nascentmc.com/podcast

In this episode of the Celebrate Kids podcast, Dr. Kathy Koch discusses the importance of mental health in teenagers and young children. You're introduced a new screening test that can help detect early signs of mental health disorders and provide early intervention. Dr. Kathy then highlights the significance of early intervention and shares that around 50 percent of lifetime mental health conditions start at the age of 14. She  acknowledges that mental health is a concern for most parents and encourages creating a rhythm for mental health screenings. In closing, Dr. Kathy gives important tips for parents as they care for their kids' mental health

Do you know that prostate cancer is the second most prevalent cancer in American men, following skin cancer? A new diagnosis of prostate cancer occurs every two minutes. We are delighted to partner with Oxford Biodynamics for today's episode with Dr. Robert Heaton, who joins us to discuss a ground-breaking new prostate cancer screening test that predicts the risk of prostate cancer with 94% accuracy, using a simple blood test. Dr. Heaton is a board-certified pathologist. He completed his medical training at Georgetown University and then spent the next twenty years in the US Navy. After finishing his residency training in pathology, Dr. Heaton became the Director of Laboratory and Clinical Support Services for the National Naval Medical Center before joining various hospital pathology labs and life sciences companies. He is currently the Laboratory Medical Director for Oxford Biodynamics at their CLIA-certified clinical lab in Maryland, where he oversees the clinical operations of their liquid biopsy blood tests. In today's episode, we dive into the details of the innovative EpiSwitch Prostate Screening test, known as the PSE, designed to confirm the presence of prostate cancer, whether symptoms are present or not. This technological advancement is a game-changer! It empowers urologists by providing a precise tool to assess whether a patient should undergo a biopsy or opt for continued monitoring. Stay tuned to learn how this simple yet powerful tool streamlines the screening process for men struggling with prostate cancer. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.   Show Highlights: At what age should men start getting checked for prostate cancer?  What the screening for prostate cancer typically entails The importance of establishing a baseline to monitor how PSA changes over time Dr. Heaton dives into the details of the EpiSwitch PSA test How men can access the EpiSwitch PSA test Dr. Heaton discusses the accuracy of the EpiSwitch PSA test What is the expected turnaround time for the EpiSwitch PSC test results? Dr. Heaton explains the role of the Epi Switch PSA test in different scenarios The revolutionary EpiSwitch Prostate Screening test has remarkable accuracy in predicting prostate cancer risk through a simple blood test. It holds immense promise for men battling prostate cancer by providing urologists with a precise diagnostic tool and offering a streamlined approach for patients facing the complexities of prostate cancer. Links: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. Oxford BioDynamics: Website LinkedIn  Facebook Twitter: @oxbiodynamics and #OBD Instagram: @oxbiodynamics YouTube: @oxfordbiodynamics PSE: Website LinkedIn Facebook Twitter: (@94percent_com) Instagram: (@get_the_pse)

Resources: and so much more at https://www.womenshealthmelbourne.com.au/blog Find us on Instagram - @knockeduppodcast Join our community! Follow Women's Health Melbourne on Facebook and Instagram (@womenshealthmelbourne), and follow Dr Raelia Lew on Instagram (@drraelialew). Have a question about women's health? Is there a specific topic you'd like us to cover? Email podcast@womenshealthmelbourne.com.au. We keep all requests anonymous. Women's Health Melbourne is a holistic care precinct, for more information about the work we do click here. Hosts: Dr Raelia Lew and Jordi MorrisonSee omnystudio.com/listener for privacy information.

Editor's Summary by Anne Rentoumis Cappola, MD, ScM, Associate Editor of JAMA, the Journal of the American Medical Association, for the October 10, 2023, issue. Related Content: Audio Highlights

Should Bert take the screening test that could possibly, MAYBE tell him if he has a chance of having cancer in the future? What do you think? Learn more about your ad choices. Visit megaphone.fm/adchoices

See omnystudio.com/listener for privacy information.

“It is better to be safe than sorry. My call to action for Aboriginal Mob across Australia is: don't be complacent; get the kit when it comes to you; do it and send back… Bowel cancer is one of the easiest cancers to treaty if it is done early.” - Aunty Jill Gallagher.

Vidcast: https://www.instagram.com/p/CtvngjiMJsY/ Combining genetic information with conventional Prostate Specific Antigen, PSA, test results sharpens the precision and the predictive value of conventional PSA tests.  Multi-disciplinary researchers at UC-San Francisco and the Stanford Cancer Institute studied 95,768 men and discovered 128 specific genetic associations with prostate cancer.  Using this data, they developed a PSA polygenic score that, when combined with conventional PSA levels was 3.4 times more predictive of aggressive prostate cancer than raw PSA values.  Such hybrid PSA testing could avoid as many as 31% of negative prostate biopsies for screening purposes and as many 12% of such biopsies for follow up after prostatic cancer therapy. https://www.nature.com/articles/s41591-023-02277-9 #psa #prostatecancer #genetics #precisiononcology

Maggie Malone, CEO of Certior Health and Dr Nick Flynn, GP and Chief Medical Officer of Certior Health joined Anton Savage who was filling in for Pat to discuss the new cancer screening test.

A new campaign featuring Waanyi Gangalidda and Erub man Trevor Tim is encouraging Aboriginal and Torres Strait Islander peoples to stay strong and healthy by doing a free bowel cancer screening test every 2 years from the age of 50. “I think it's very important that our people, our mob, do the free test. We're talking about leading the way for our people, we need to close the gap and we need our mob to be living longer,” Trevor Tim.

The gold-standard antibiotic screening test has fundamental issues, but UCSB researchers have developed a new test -- one that's much more accurate. The study's lead author speaks with KCSB's Joyce Chi on why the healthcare industry can't let go of the gold-standard test, and on what the new test means for fighting antibiotic resistance.

  Vidcast:  https://youtu.be/AXAhkfaBmEA   A novel cervical swab test can identify pre-cancerous cervical cell changes some 4 years before they trigger cancer.  Austrian and British oncologic researchers have developed a test that analyzes the levels of DNA methylation in cervical cells captured on the cotton swab.   The test detects cervical cell cancer transformation with a 92.7% sensitivity for women over the age of 30 years.  When this test was performed on 428 cervical cell samples free of overt cancer but at risk for developing cancer due to the presence of human papilloma virus, the test correctly identified 55% of the women who would later develop overt cervical cancer over a 1-4 year period.   Not a perfect result but a very promising start that will become more precise with additional work.  BTW: the same test can forecast ovarian and breast cancer.   https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01116-9   #cervicalcancer #dna #methylation #hpv #carcinomainsitu  

Listen to the SBS Sinhala radio interview with Dr.Lakmini Busnayaka from Brisbane explaining about the eligibility criteria for mammogram test in Australia and the must known facts about diagnostic test. - පියයුරු පිළිකා කල් ඇතුව හඳුනාගැනීම සඳහා භාවිතා කරන මැමෝග්‍රම් පරීක්ෂණය පිළිබඳ ඔබ දැන ගත යුතුම වැදගත් තොරතුරු දැන ගන්න මේ ගුවන්විදුලි සාකච්ඡාවට සවන් දෙන්න.

Avrio Genetics (267-329-9319) in Allentown, PA helps you determine whether you're at risk for fibromyalgia. We've recently launched a new genetic screening test for the condition. Learn more at https://avriogenetics.com (https://avriogenetics.com)

In unserer Nachmittagsfolge begrüßen wir heute Meik Baumeister, Co-Founder und CEO von Cardisio, und sprechen über die Finanzierungsrunde i.H.v. 3,5 Millionen Euro. Cardisio ist ein Mobile-Health-Tech-Unternehmen, das KI für den - Unternehmensangaben zufolge - weltweit ersten und einzigen nicht-invasiven Screening-Test für die Früherkennung von Herzkrankheiten nutzt. Menschen mit Herzerkrankungen sind in der Regel bis zum Auftreten eines Herzinfarkts symptomfrei. Der Cardisiographie-Test soll Herzkrankheiten frühzeitig erkennen und so eine vorbeugende Behandlung ermöglichen. Und das, bevor es zu einem potenziell tödlichen Herzinfarkt kommt. Die Vorteile einer Cardisiographie ist die einfache Handhabung, die Genauigkeit und die kostengünstige Durchführung. Eine Gruppe privater Investoren hat sich jetzt mit insgesamt 3,5 Millionen Euro an dem Startup beteiligt. Zu den individuellen Geldgebern gehören Jim Davidson, der Mitbegründer von Silver Lake, und Shawn O'Neill, Geschäftsführer bei Silver Lake Waterman. Ergänzt wird die Runde durch mehrere neue und bereits existierende Privatinvestoren aus den USA und Deutschland. Wenn auch Du Dein Lieblingstool bewerten willst, schreibe eine Review auf OMR Reviews. Dafür erhältst du einen 20€ Amazon Gutschein. https://moin.omr.com/insider

I know Podcasts are meant to be about true crime, I know, not paps smears and pregnancy! This topic is too important not to soar up the podcast charts! In today's super-fast episode I talk about the Cervical Screening Test (CST) its importance and the facts about CST and pregnancy.*Spoiler alert - it is safe to have a CST when you're pregnant*The benefits of being on top of CST ( the new form of pap smear) far outweigh the uncomfortable bits.  In the past five years, the way CST are undertaken have changed so CST is a really good topic to add to your list of questions to ask your GP.For information on how a CST works visit herehttps://www.health.gov.au/initiatives-and-programs/national-cervical-screening-program/getting-a-cervical-screening-test/how-cervical-screening-worksSome extra information from The Royal Australian and New Zealand College of Obstetricians and Gynaecologists https://ranzcog.edu.au/womens-health/patient-information-resources/cervical-screening-in-australiaThis episode is fact-checked and supported by www.familyhq.com.au - thanks Liz and Sarah.For more on the suite set, please visit us at https://www.thesuiteset.com/pages/our-gift-to-you

Troy Chats with Katanning Mum Rachel on Changes to The WA Infant Screening See omnystudio.com/listener for privacy information.

In this latest SBS Hindi News bulletin: Five commissioners to lead Victoria's Australia-first inquiry into injustices committed against Indigenous people; Conflict in Gaza escalates further; Australia's Indian Premier League contingent could return home as early as this weekend and more.

Australian News: 14 May 2021 – Fridat Read by Selvi - ஆஸ்திரேலிய செய்திகள்: 14 மே 2021 வெள்ளிக்கிழமை வாசித்தவர்: செல்வி

The director of Te Tātai Hauora o Hine, the Centre for Women's Health Research at Victoria University, wants a less invasive cervical screening test rolled out as soon as possible. The government has announced a $55 million funding boost to make the test available, but not until 2023. Currently there are 400,000 New Zealanders who are not getting regular smear tests.  Susie Ferguson spoke to Te Tātai Hauora o Hine founder Bev Lawton.  

Health workers at the frontline of fighting terrible rates of cervical cancer among Māori say a new, easier test, will save lives but isn't a one-stop fix. The government will introduce a type of swab to test for the HPV virus which causes 99 percent of cervical cancers. Women can do it themselves and it's hoped it will rein in cases, particularly among Māori women, who are two and a half times more likely to die from the disease. Health correspondent Rowan Quinn reports.  

Health workers at the frontline of fighting terrible rates of cervical cancer among Māori say a new, easier test, will save lives but isn't a one-stop fix. The government will introduce a type of swab to test for the HPV virus which causes 99 percent of cervical cancers. Women can do it themselves and it's hoped it will rein in cases, particularly among Māori women, who are two and a half times more likely to die from the disease. Health correspondent Rowan Quinn reports.  

The director of Te Tātai Hauora o Hine, the Centre for Women's Health Research at Victoria University, wants a less invasive cervical screening test rolled out as soon as possible. The government has announced a $55 million funding boost to make the test available, but not until 2023. Currently there are 400,000 New Zealanders who are not getting regular smear tests.  Susie Ferguson spoke to Te Tātai Hauora o Hine founder Bev Lawton.  

We're always looking for easier ways to detect cancer earlier. It gives our patients the opportunity for better prognoses.    Today we're talking about one of the new ways to detect cancer early. It's called the Nu.Q Cancer Screening Test, and it was developed by a joint effort from a company called Volition and Texas A&M College of Veterinary Medicine.   Joining me today is Dr. Heather Robles, who led the research at Texas A&M in order to make this test possible.    Dr. Heather Robles is a board-certified veterinary oncologist and Chief Medical Officer of Volition Veterinary Diagnostics Development. She is also the Professor of Oncology at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, along with the Assistant Department Head of Research and the Dr. Fred A. and Vola N. Palmer Chair in Comparative Oncology.    Join us as we spread the word about this test and answer as many questions as we can in this episode.    Resources Mentioned: Volition Veterinary - Nu.Q Cancer Screening Test  Texas A&M GI Lab - Sample Processing/Collection Information    Full show notes and links mentioned in the episode are available at www.caninecanceracademy.com/podcast-ep-35   Don’t forget to say hello on Instagram @thecaninecaneracademy and on Facebook Canine Cancer Academy

The Newborn Screening Test is a quick, safe and effective way to identify babies at risk of certain serious conditions. Screening is the only way to identify affected babies early as there may be no signs or symptoms of illness at birth. By the time affected babies show symptoms, their development or health may already be impaired. Early diagnosis allows early treatment or management to prevent or reduce complications. Follow us on Instagram: https://www.instagram.com/yourekiddingright.pod/ and  Facebook: https://www.facebook.com/yourekiddingrightpod-107273607638323/ Our email is yourekiddingrightpod@gmail.com Make sure you hit SUBSCRIBE/FOLLOW so you don’t miss out on any pearls of wisdom and RATE if you can to help other people find us! (This isn’t individual medical advice, please use your own clinical judgement and local guidelines when caring for your patients)

What's the verdict, Jonesy? See omnystudio.com/listener for privacy information.

The rollout of a cervical screening test that patients can do themselves has been delayed again, with doctors saying some people will die unnecessarily as a result. The alternative to the current speculum test was meant to be introduced next year - after already being delayed three years. Professor Beverley Lawton is Director of Te Tatai Hauora o Hine, the Centre for Women's Health Research, at Victoria University of Wellington and speaks to Corin Dann.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.21.214395v1?rss=1 Authors: Milne, A. E., Bianco, R., Poole, K. C., Zhao, S., Billig, A. J., Chait, M. E. Abstract: Online experimental platforms can be used as an alternative, or complement, to lab-based research. However, when conducting auditory experiments via online methods, the researcher has limited control over the participants' listening environment. We offer a new method to probe one aspect of that environment, headphone use. Headphones not only provide better control of sound presentation but can also "shield" the listener from background noise. Here we present a rapid (< 3 minute) headphone screening test based on Huggins Pitch (HP), a perceptual phenomenon that can only be detected when stimuli are presented dichotically. We validate this test using a cohort of "Trusted" online participants who completed the test using both headphones and loudspeakers. The same participants also trialled a widely used headphone test (AP test; Woods et al., 2017). We demonstrate that compared to the AP test, the HP test has a higher selectively for headphone users, rendering it as a compelling alternative to the existing screening method. Overall, the new HP test correctly detects 80% of headphone users and has a false positive rate of 20%. Moreover, we demonstrate that there is little overlap between participants who pass both HP and AP tests over loudspeakers. Therefore, combining the two tests can lower the false positive rate to ~7% (but at the expense of an increased false negative rate). This should be useful in situations where headphone use is particularly critical (e.g. dichotic or spatial manipulations). An implementation of the new test is available with JavaScript and through Gorilla (gorilla.sc). Copy rights belong to original authors. Visit the link for more info

JEST allow applicants who wish to join premium institutes for natural and life sciences program for Ph.D. and Integrated Ph.D. i.e. MSc + Ph.D. During the last podcast, we got introduced to one such premium institute i.e. Tata Institute of Fundamental Research. So, for the students who wish to choose research and become leading scientists they must know these institutes and the kind of program they offer and their eligibility criteria. So, if your broad interests are Physics, Chemistry, Biology, Mathematics, Neurosciences, computer sciences then you must look at JEST and the participating institutes. Therefore, let me begin by introducing these participating institutes and maybe a little bit more about them. This podcast explore on all the participating institutes and their eligibility criteria. --- Send in a voice message: https://anchor.fm/vijay-sonawane/message

Thank you for visiting this VETgirl podcast page! While our veterinary podcasts are available to everyone for free, only VETgirl ELITE members can get CE credit for listening, plus access to the transcript of the podcast (where applicable). VETgirl ELITE members also receive 100+ hours of RACE-approved, online veterinary CE/year in the form of webinars (including small animal, large animal, veterinary technician, and leadership), "how to" videos and Real Life Rounds when you have time. VETgirl ELITE members also have access to our VETgirl forum where you can interact with colleagues and specialists and get clinical support and tips!

In this VETgirl online veterinary CE podcast, we review whether cardiac troponin I is an accurate screening test for the diagnosis of Hypertrophic Cardiomyopathy (HCM) in cats. Hypertrophic cardiomyopathy is defined as concentric hypertrophy of the left ventricle in the absence of any other identifiable cause, in particular systemic hypertension and hyperthyroidism in cats.

In this VETgirl online veterinary CE podcast, we review whether cardiac troponin I is an accurate screening test for the diagnosis of Hypertrophic Cardiomyopathy (HCM) in cats. Hypertrophic cardiomyopathy is defined as concentric hypertrophy of the left ventricle in the absence of any other identifiable cause, in particular systemic hypertension and hyperthyroidism in cats.

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

Don't let embarrassment from doing a cervical cancer screening test kill you. - Txhob cia txoj kev txaj muag ua rau koj tas sim neej vim tsis xav mus sim seb puas puas yog koj mob kab mob cancer tsev me nyuam!

  I was intrigued to speak with Dr. Herbert Brill of William Osler Health System regarding the study he did with other health care professionals on the efficacy of the DGP blood test with children referred for further consultation in screening for celiac disease.  The study focussed on children with a negative TTG test and a positive DGP test.  The study concluded the test was not useful in screening children for celiac disease in the general population.  You can find an article about the study on the William Osler Health System website or at the following link – http://bit.ly/DGPTestStudy This study was brought to my attention by a post from Ellen Bayens of The Celiac Scene.  You can subscribe to her newsletter at www.theceliacscene.com.  Thanks Ellen! Sue's Websites and Social Media – Podcast https://acanadianceliacpodcast.libsyn.com Podcast Blog – https://www.acanadianceliacblog.com Facebook - @acanadianceliacpodcast Twitter – CeliacPodcastCA Email – acdnceliacpodcast@gmail.com Baking Website – https://www.suesglutenfreebaking.com Instagram - @suesgfbaking YouTube - https://www.youtube.com/playlist?list=PLUVGfpD4eJwwSc_YjkGagza06yYe3ApzL      (search Sues Gluten Free Baking) Email – sue@suesglutenfreebaking.com Other Podcast – Gluten Free Weigh In – https://glutenfreeweighin.libsyn.com

  I was intrigued to speak with Dr. Herbert Brill of William Osler Health System regarding the study he did with other health care professionals on the efficacy of the DGP blood test with children referred for further consultation in screening for celiac disease.  The study focussed on children with a negative TTG test and a positive DGP test.  The study concluded the test was not useful in screening children for celiac disease in the general population.  You can find an article about the study on the William Osler Health System website or at the following link – http://bit.ly/DGPTestStudy This study was brought to my attention by a post from Ellen Bayens of The Celiac Scene.  You can subscribe to her newsletter at www.theceliacscene.com.  Thanks Ellen! Sue's Websites and Social Media – Podcast https://acanadianceliacpodcast.libsyn.com Podcast Blog – https://www.acanadianceliacblog.com Facebook - @acanadianceliacpodcast Twitter – CeliacPodcastCA Email – acdnceliacpodcast@gmail.com Baking Website – https://www.suesglutenfreebaking.com Instagram - @suesgfbaking YouTube - https://www.youtube.com/playlist?list=PLUVGfpD4eJwwSc_YjkGagza06yYe3ApzL      (search Sues Gluten Free Baking) Email – sue@suesglutenfreebaking.com Other Podcast – Gluten Free Weigh In – https://glutenfreeweighin.libsyn.com

Questa sera a POP si parla di Futuro Anteriore, spettacolo di Produzione Ferrara Off, con la drammaturga Margherita Mauro e il regista Giulio Costa. fra gli interpreti anche Matilde, per uno spettacolo sul futuro della terza età che sarà in prima Nazionale questo weekend a Ferrara Off http://www.ferraraoff.it/futuro-anteriore/

There is no golden standard on preparing a screening test for interpreting students. You are supposed to find your own way. In this article I would like to share my approach. Screening test is a must: For one, not every student can become a simultaneous interpreter. Giving false hopes to young minds will only increase their desperation before your realize it is too late. Second, interpreter trainers are usually professional interpreters and they do not have the time and energy needed […]

In this episode we talk about the health effects of Chocolate, Diabetes, a Screening Test and spin the Wheel of Medicine. We hope you join us as we dive deep into medicine so you don't have to. We present the best studies and research in easy to understand and entertaining ways. We gladly accept show topics and ideas from our listeners.

Dogs (and cats) having a crisis as a result of hypoadrenocorticism (Addisonian crisis) can be in a life-threatening state and this represents one of the true small animal emergencies. Stabilisation of these patients starts with appropriately aggressive intravenous fluid therapy as the first priority and treatment for clinically significant hyperkalaemia and hypoglycaemia may also be needed very early on. Intravenous glucocorticoids are typically then required to continue stabilisation. In this episode I discuss ten talking points relating to canine hypoadrenocorticism, namely: “The Great Pretender” Likely Genetic Basis Aldosterone may be low in ‘atypical’ cases Hypoglycaemia may be severe Bradycardia is not always present and not just due to hyperkalaemia ACTH stimulation test provides definitive diagnosis Single resting plasma cortisol may be useful for screening – but limited role in emergencies? Intravenous fluid therapy Client communication and education Prognosis is good with appropriate management – yey!   Click Here For Your FREE Copy of a Transcript of This Episode   PAPERS that helped inspire some of the content for this episode are: Baumstark ME, Sieber-Ruckstuhl NS, Mϋller C, et al. Evaluation of Aldosterone Concentrations in Dogs with Hypoadrenocorticism. J Vet Intern Med 2014; 28:154–159. (Open access online) Boag AM, Catchpole B. A Review of the Genetics of Hypoadrenocorticism. Topics in Companion Animal Medicine 2015 (Accepted manuscript pending publication). Bovens C, Tennant K, Reeve J, Murphy KF. Basal Serum Cortisol Concentration as a Screening Test for Hypoadrenocorticism in Dogs. J Vet Intern Med 2014; 28:1541–1545. (Open access online) Lennon EM, Boyle TE, Hutchins RG, et al. Use of basal serum or plasma cortisol concentrations to rule out a diagnosis  of hypoadrenocorticism in dogs:  123 cases (2000–2005). J Am Vet Med Assoc 2007; 231:413–416. (Abstract)

Sat, 21 Jul 2012 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/17336/ https://edoc.ub.uni-muenchen.de/17336/1/Roos_Anja.pdf Roos, Anja Alexandra

New Screening Test for Antibiotic Residue

Audio Journal of Medicine, August 8th 2007 Visual Cervix Cancer Screening Test: Cheap and Effective in the Developing World REFERENCE: Lancet 2007;370:398-406 RENGASWAMY SANKARANARAYANAN, International Agency for Research on Cancer, Lyon An inexpensive visual cervix cancer-screening test has proved its worth in India according to a publication in the Lancet. Inspecting the cervix visually after applying 4% acetic acid can reduce the incidence and mortality from cervical cancer in developing countries. Nicola Solomon interviewed Rengaswamy Sankaranarayanan.

Hintergrund: Die konventionelle Weiss-auf-Weiss-Perimetrie zählt zum Goldstandard der Glaukom-Diagnostik. Der Verlust achromatischer Kontrastempfindlichkeit ist aber als sensorischer Ausfall ein Spätsymptom und markiert den Beginn einer lokalen Erblindung. In diversen Studien konnte nachgewiesen werden, dass ein Verlust an chromatischer Kontrastempfindlichkeit im kurzwelligen Bereich des Farbspektrums perimetrischen Gesichtsfelddefekten vorausgehen kann. Eine quantitative Bestimmung peripherer Farbkontrastempfindlichkeit erlaubt der Arden-Computergraphik-Farbtest. Ziel dieser Querschnittsstudie war zum einen, Unterschiede in der peripheren Farbkontrast-Sensitivität zwischen einer größeren Gruppe von Glaukom-Patienten (n=50), sogenannten präperimetrischen Diagnosegruppen (Patienten mit okulärer Hypertension, Patienten mit V.a. Glaukom, n=41) und augengesunden Patienten (n=19) zu finden, und zum anderen die Bestimmung von Zusammenhängen zwischen peripheren Farbkontrast-Verlusten im kurzwelligem Bereich (Tritanachse) und zu diesem Zeitpunkt gegebenenfalls bestehenden Pathologien der Papillenmorphologie. Hierfür wurde sowohl der Mittelwert der Farbkontrastempfindlichkeit der einzelnen Quadranten, als auch die Farbkontrastempfindlichkeit eines einzelnen Quadranten (hier „Field Low Left“) mit den entsprechenden HRT II-Parametern (global oder ein einzelner Sektor) korreliert. Patienten und Methodik: Insgesamt wurden 110 Patienten in die Studie miteingeschlossen, und in die Diagnosegruppen „Glaukom“ (n=50), „V.a. Glaukom“ (n=26), „OCH“ (n=13) und „Augengesund“ (n=21) eingeteilt. Bei allen Patienten wurde eine Messung mit dem HRT II zur Erhebung quantitativer Papillen-Mekmale, und der Arden-Computergraphik-Farbtest durchgeführt. Darüber hinaus erfolgte jeweils eine Gesichtsfelduntersuchung, eine Visusbestimmung, eine allgemeine Anamnese, eine ausführliche Medikamentenanamnese und die Bestimmung der im bisherigen Krankheitsverlauf maximalen Tensiowerte. Die Papillenmorphologie wurde anhand qualitativer Merkmale von einem erfahrenen Untersucher in folgende Gruppen eingeteilt: „glaukomatöser Papillenbefund“, „grenzwertiger Papillenbefund“ und „unauffälliger Papillenbefund“. Nichtparametrische Tests: Im Kruskall-Wallis-Test zeigten die Variablen „Field mean“ und „Field LowL“ einen signifkanten Unterschied (p=0,039 bzw. p=0,023) zwischen den Diagnosegruppen. Im Mann-Whitney-Test erfüllen „Field LowL“-Werte die Kriterien einer Zusammenfassung 66 Signifikanz-Adjustierung und unterscheiden sich zwischen den Diagnosgruppen „Glaukom“ und „Augengesund“ statistisch signifkant (p=0,006). Ergebnisse der bivariaten Korrelation: Sowohl im Gesamtkollektiv, als auch in der Diagnosegruppe „Glaukom“ zeigte der Farbkontrast-Schwellenwert des unteren linken Quadranten („Field LowL“) im Unterschied zum Mittelwert der Farbkontrast-Schwellenwerte der Einzel-Quadranten („Field mean“) die stärkeren und häüfigeren Zusammenhänge zur Papillenmorphologie. In der Gruppe „Glaukom“ zeigte „Field LowL“ statistisch signifikante Zusammenhänge zu den meisten stereometrischen Parametern des HRT II: „cup area“ (r=0,547, p=0,000), „rim area“ (r=0,456, p=0,001), „cup/disc area ratio“ (r=0,525, p=0,000), „rim/disc area ratio“ (r=0,525, p=0,000), „cup volume“ (0,453, p=0,001), „rim volume“ (r=0,409, p=0,003), „height variation contour (r=0,38, p=0,006), „cup shape measure“ (r=0,345, p=0,012), „mean RNFL thickness“ (r=0,404, p=0,004) und „RNFL cross sectional area“ (r=0,381, p=0,006). In den präperimetrischen Diagnosegruppen „V.a. Glaukom“ und „OCH“ konnte nur in der „OCH“-Gruppe ein statistisch hochsignifikanter Zusammenhang (r=0,764, p=0,001) zwischen „Field LowL“ und dem stereometrischen Paramter „height variation contour“ gefunden werden. Ergebnisse der partiellen Korrelation: Bei Konstanthalten des Einflusses der Variable „age“ in der Glaukom-Gruppe zeigt „Field mean“ einen moderaten, statistisch signifikanten Zusammenhang zu den HRT-II-Parametern „height variation contour“ (r=0,348, p=0,008) und „CLM temporal-inferior“ (r=0,371, p=0,005). Bei Herauspartialisieren der Variable „disc area“ konnten alle in der bivariaten Korrelation gefundenen Zusammenhänge beibehalten werden. Bei Konstanthalten des Einflusses der mittleren Defekttiefe der Gesichtsfelduntersuchung („MD in dB“) zeigten sich keine statistisch signifikanten Zusammenhänge. Im Unterschied dazu zeigte der Quadranten-Schwellenwert „Field LowL“ in der Glaukom-Gruppe sowohl bei Konstanthalten des Einflusses des Alters, als auch der Papillengröße, als auch der mittleren Defekttiefe der Gesichtsfeld-Untersuchung statistisch signifikante Zusammenhänge zu allen auch in der Pearson-Korrelation gefundenen stereometrischen HRT-II-Parametern, wobei die Zusammenhangs-Stärke bei Herauspartialisieren von „disc area“ und „MD in dB“ schwächer ausfiel als in der bivariaten Korrelation; bezüglich der Kontrollvariable „MD in dB“ sind es: „cup area“ (r=0,457, p=0,001), „rim area“ (r=0,290, p=0,033), „cup/disc area ratio“ (r=0,419, p=0,003), „rim/disc area ratio“ (r=0,419, p=0,003), „cup volume“ (0,333, p=0,017), „rim volume“ (r=0,319, p=0,021), „height variation contour (r=0,304, p=0,027), „cup shape measure“ (r=0,260, Zusammenfassung 67 p=0,05), „mean RNFL thickness“ (r=0,411, p=0,004) und „RNFL cross sectional area“ (r=0,354, p=0,012). Der in der bivariaten Korrelation in der „OCH“-Gruppe gefundene, starke Zusammenhang zwischen „Field LowL“ und dem stereometrischen Paramter „height variation contour“ zeigte sich auch bei Herauspartialisieren des Alters und der mittlerern Defekttiefe der Gesichtsfeld-Untersuchung: r=0,686, p=0,01 bzw. r=0,794, p=0,002, jedoch nicht bei Herauspartialisieren der Variablen „disc area“ (r=0,001, p=0,499). Der überwiegende Teil der in den präperimetrischen Diagnosegruppen gefundenen Zusammenhänge zeigte sich jedoch statistisch nicht signifikant. Ergebnisse der Regressionsanalyse: Sowohl nichtstereometrische Parameter wie Alter, Augeninnendruck und Ergebnisse der Gesichtsfelduntersuchung, als auch die stereometrischen Parameter des Heidelberg-Retina-Tomographen-II zeigen einen statistisch signifikanten Einfluss auf die Ergebnisse des Computergraphik-Farbtests. Während der Einfluss von nichtstereometrischen Parametern einen stärkeren Einfluss auf die Variable „Field mean“ als auf die Variable „Field LowL“ aufweist (r2=0,445, p=0,000 versus r2=0,359, p=0,001), verhält es sich mit den stereometrischen HRT-II-Parametern umgekehrt: Sie zeigen den stärkeren Einfluss auf die Variable „Field LowL“ (r2=0,603, p=0,000 versus r2=0,188, p=0,048). Schlussfolgerung: Die Diagnose „Glaukom“ setzt sich aus den Ergebnissen unterschiedlicher Untersuchungen zusammen. Zu den Eckpfeilern der Glaukom-Diagnostik zählen Papillenveränderungen, erhöhter Augeninnendruck, Gesichtsfelddefekte und schließlich das Alter und die Familienanamnese eines Patienten. In den letzten Jahrzehnten hielt vor allem die qualitative Messung der Papillenmorphologie und umgebender Netzhaut-Strukturen (HRT, OCT, GDX, u.a.) Einzug in die Glaukom-Diagnostik. Gemeinsam mit psychophysikalischen Tests, die Gesichtfelddefekte nachweislich vor dem Verlust an Kontrastempfindlichkeit in der Weiss-auf-Weiss-Perimetrie aufzeigen, erweitert und ergänzt sie die klassische Glaukom-Diagnostik. In dieser Arbeit konnte zunächst bestätigt werden, dass sich die Ergebnisse des Arden-Computergraphik-Farbtests bei einer erstmals großen Gruppe von Glaukom-Patienten signifikant von den Ergebnissen der Kontrollgruppe augengesunder Patienten unterscheiden. Im weiteren konnte erstmals gezeigt werden, dass auch unter Berücksichtigung des Alters und der Ergebnisse der Gesichtsfelduntersuchung ein überwiegend hochsignifikanter Zusammenhang zwischen einem funktionellen Test (Arden- Computergraphik-Farbtest) und einem modernen, rein morphologischen Test (HRT II) bei Glaukompatienten besteht. Die Einzel-Quadranten-Analyse (hier der funktionell linke untere Zusammenfassung 68 Quadrant) zeigte hier die stärksten Zusammanhänge zu den Parametern „cup area“, „rim area“, cup/disc area ratio“ und „rim/disc area ratio“ und ist dem Mittelwert der Schwellenwerte aller Quadranten überlegen. Die statistisch signifikanten Veränderungen entsprechen dem temporal-superioren Bereich der Papille, in dem in frühen und in mäßig fortgeschrittenen Glaukom-Stadien erste Verluste des neuroretinalen Randsaums zu beschrieben sind (Tuulonen A & Airaksinen PJ, 1991, Jonas JB et al., 1993). Dem Arden-Computergraphik-Farbtest kommt somit ein hoher Stellenwert in der Glaukomdiagnostik zu. Die Kombination von Funktion und Morphologie erhöht die Validität in der Glaukomdiagnostik; eine Eignung als Screening-Test, der zwischen präperimetrischen Diagnosegruppen unterscheidet, konnte allerdings nicht bestätigt werden.

Today's podcast presents a review of a psychological study of a simple screening test for Autism that can be used with infants of 12 months of age. The study presents correlational data that can be helpful for pediatricians and parents to use with infants at 12 months of age. The test is simple and harmless, but it cannot be used to defintely prove whether a child has Autism.

Die Glykogen-Speicherkrankheit (GSD) ist eine seltene Stoffwechselerkrankung, die in verschiedenen Ausprägungen (Typen) vorkommt. Im ersten Teil der Arbeit wird durch Messung der Enzymaktivität von saurer α-Glukosidase und der Enzymaktivität des Branchingenzyms ein Screening-Test durchgeführt. Im zweiten Teil wird durch Genanalyse als diagnostische Methode die Erklärung der Erkrankung auf molekulargenetischer Ebene erforscht, um den Zusammenhang zwischen dem Geno- und Phenotyp zu verstehen.